Skip to main content

Table 1 Demographics and echocardiographic findings of patient cohort

From: Cyclophosphamide use in treatment of refractory Kawasaki disease with coronary artery aneurysms

Total number of CYC treated patients, n

10

Male sex

70%

Median Age at Diagnosis of KD (range)

2 years (4 months – 5 years)

Race

 • White

• 4

 • Asian

• 2

 • Hispanic

• 3

 • Not available

• 1

Complete KD criteria

50%

Median Day of Illness at 1st IVIG (range)

7 (4–10)

Median Day of Illness at CYCa (range)

22.5 (10–36)

Two doses of CYC

30%

Adjunctive Therapies before CYC

 • Glucocorticoids

• 100%

 • Infliximab

• 40%

 • Cyclosporine A

• 20%

 • Anakinra

• 10%

Median Baseline LADb Z score (range)

3.8 (0.68–13.4)

Median Baseline RCAc Z score (range)

2.1 (0.1–12.16)

Median LAD Z Max during admission (range)d

15.7 (4.7–29.6)

Median RCA Z Max during admission (range) d

11.8 (2.0–21.06)

Number of patients with bilateral aneurysms (n, %)

9 (90%)

Number of patients with giant aneurysms (n, %)

8 (80%)

  1. aCyclophosphamide bLeft Anterior Descending Artery; cRight Coronary Artery
  2. dZ max: largest measurement of LAD or RCA, at any point of the course